These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10382869)

  • 41. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
    Felmingham D; Robbins MJ; Ingley K; Mathias I; Bhogal H; Leakey A; Ridgway GL; Grüneberg RN
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
    Tali-Maamar H; Tebbal S; Rahal K
    Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative in vitro activity of gemifloxacin.
    King A; May J; French G; Phillips I
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Results of antimicrobial susceptibilities of strains clinically isolated at 8 institutions in Hiroshima City to major oral antimicrobial drugs, mainly new quinolone drugs. Hiroshima Levofloxacin Susceptibility Surveillance Group].
    Fujiue Y; Kuwabara M; Muroki K; Kohara T; Itaha H; Yamasaki M; Sasaki M; Onimura K; Shigemitsu M; Kashiyama S
    Jpn J Antibiot; 2000 Jun; 53(6):409-21. PubMed ID: 10955237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers.
    Diekema DJ; Jones RN; Rolston KV
    Diagn Microbiol Infect Dis; 1999 May; 34(1):37-43. PubMed ID: 10342106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
    Hoogkamp-Korstanje JA; Dirks-Go SI; Kabel P; Manson WL; Stobberingh EE; Vreede RW; Davies BI
    J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In vitro activities of 23 antimicrobial agents against 4,993 gram-positive and gram-negative bacterial strains isolated from multicenter of Japan during 1994--in vitro susceptibility surveillance.Levofloxacin-Surveillance Group].
    Yamaguchi K; Ohno A; Kashitani F; Iwata M; Shimizu Y; Sato S; Matsumoto I; Itoh M; Funato T; Tsujio Y; Nagasawa M; Tachibana M; Kanno H; Matsuda K; Okada J; Takaya H; Nakamura T; Igari J; Sugimoto K; Oguri T; Toyoshima S; Okada M; Nakai T; Kuwabara M; Nagasawa Z
    Jpn J Antibiot; 1999 Feb; 52(2):75-92. PubMed ID: 10221176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review of the antimicrobial activity of the fluoroquinolones.
    Maple P; Brumfitt W; Hamilton-Miller JM
    J Chemother; 1990 Oct; 2(5):280-94. PubMed ID: 2128638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria.
    Spangler SK; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Jan; 44(1):186-9. PubMed ID: 10602746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A review of clinical trials with fluoroquinolones with an emphasis on new agents.
    Blondeau JM
    Expert Opin Investig Drugs; 2000 Feb; 9(2):383-413. PubMed ID: 11060684
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance.
    Watts JL; Salmon SA; Sanchez MS; Yancey RJ
    Antimicrob Agents Chemother; 1997 May; 41(5):1190-2. PubMed ID: 9145899
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluoroquinolones.
    O'Donnell JA; Gelone SP
    Infect Dis Clin North Am; 2000 Jun; 14(2):489-513, xi. PubMed ID: 10829268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety.
    Geddes AM
    Expert Opin Investig Drugs; 1999 Apr; 8(4):487-505. PubMed ID: 15992094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis of possible metabolites of 1-cyclopropyl-1,4-dihydro-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)- 4-oxo-3-quinolinecarboxylic acid (Grepafloxacin, OPC-17116).
    Morita S; Otsubo K; Matsubara J; Ohtani T; Kawano Y; Ohmori K; Ohguro K; Uchida M
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2246-52. PubMed ID: 8582026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant gram-positive pathogens.
    Roychoudhury S; Ledoussal B
    Curr Drug Targets Infect Disord; 2002 Mar; 2(1):51-65. PubMed ID: 12462153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impermeability to quinolones in gram-positive and gram-negative bacteria.
    Bryan LE; Bedard J
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):232-9. PubMed ID: 1864283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.